Induction of IL-1 Ra in Resistant and Responsive Hepatitis C Patients Following Treatment with IFN-con 1
暂无分享,去创建一个
Milton W. Taylor | M. Morrisey | S. Cotler | D. Jensen | A. Conrad | J. Albrecht | M. Ferris | T. Craft | K. R. Reddy | K. Reddy
[1] D. Ganger,et al. An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[2] G. Fantuzzi,et al. Production of IL‐1 receptor antagonist by hepatocytes is regulated as an acute‐phase protein in vivo , 2001, European journal of immunology.
[3] M. Shiffman,et al. Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. , 2000, Antiviral research.
[4] A. Neumann,et al. Hepatitis C Virus Kinetics , 1999, Antiviral therapy.
[5] T. Layden,et al. Hepatitis C viral dynamics. , 1999, Clinics in liver disease.
[6] M. Jackson,et al. Comparison of cytotoxic T‐lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals , 1999, Journal of medical virology.
[7] A Sette,et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.
[8] M. Davis,et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[9] P. Transidico,et al. Characterization of type II intracellular IL‐1 receptor antagonist (IL‐1ra3): a depot IL‐1ra , 1999, European journal of immunology.
[10] J. McHutchison,et al. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. , 1999, Seminars in liver disease.
[11] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[12] G. Davis,et al. Intrahepatic hepatitis C virus–specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C , 1998, Hepatology.
[13] M. Katze,et al. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. , 1998, Pharmacology & therapeutics.
[14] A. Sanyal,et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C , 1997, Hepatology.
[15] F. Capron,et al. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment. , 1997, Journal of hepatology.
[16] L. Blatt,et al. Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[17] H. Tilg,et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. , 1993, Journal of immunology.
[18] E. Maeyer,et al. Immuno-modulating properties of interferons. , 1982 .
[19] E. de Maeyer,et al. Immuno-modulating properties of interferons. , 1982, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.